Isomorphic Labs Raises $5B Series C From Greenoaks and Sequoia, Six Months After $2.1B
Isomorphic Labs said on November 17 it raised $5 billion in Series C funding co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz and other new investors, continued significant investment from Alphabet and participation from all existing investors, including Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund. It raised $2.1 billion in May. The company did not disclose a valuation; Bloomberg had reported the round would value it at about $50 billion. Hassabis told Bloomberg the money will speed its move to clinical trials but gave no updated target, and no regulator has yet approved an AI-designed drug.

Investors have now put more than $7 billion into Isomorphic Labs in six months, and by its own account none of its drugs has yet entered a clinical trial. The Alphabet drug-design company, run by Demis Hassabis, says it has raised a $5 billion Series C, more than double the $2.1 billion Series B it raised in May. The money buys time and compute for a platform whose clinical proof is, by the company's own account, still ahead of it.
The round#
Isomorphic said on November 17 that the round was co-led by Greenoaks and Sequoia Capital, alongside Andreessen Horowitz and several other new investors, with "continued significant investment from Alphabet". All existing investors took part: Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund. It says it is scaling its proprietary drug design engine, IsoDDE, and its pipeline of therapeutic candidates designed with AI.
The company did not disclose a valuation, Bloomberg reported, according to The Next Web; Bloomberg had reported earlier this month that the round would value Isomorphic at about $50 billion. CNBC notes the raise comes three and a half months after Hassabis stepped back as chief executive of Google DeepMind, and cites Dealroom data showing drug-discovery startups have raised a record $23.2 billion in 2026.
What the money is for#
"This round enables us to accelerate our progress: building foundational biology models, deepening our systemic disease understanding, and driving our first therapeutic programs towards clinical trials," Hassabis said, as quoted by CNBC. He told Bloomberg the company is trying to build "a platform to do hundreds of drugs a year", that it has more than 20 programmes under way and that it plans to move beyond small molecules into other drug types, The Next Web reported. Its pharmaceutical partners include Eli Lilly, Novartis and Johnson & Johnson.
On timing he was less specific. Hassabis said in January he expected the first clinical trials by the end of 2026; he would not give Bloomberg an updated target, saying only that the company is on track with regulatory submissions and will have more to announce in 2027. Sequoia partner Konstantine Buhler told Bloomberg the firm invested because Isomorphic has found scaling laws for its models, meaning performance keeps improving with more compute and data.
Limits#
- The valuation is Bloomberg's earlier reporting, not a company figure.
- The claims of positive preclinical results and scaling laws are the company's and an investor's; Isomorphic has published no independent evaluation of IsoDDE in what we read.
- No regulator has approved an AI-designed drug, Bloomberg noted, and Isomorphic has not said when its first trial will start.
- We could not open Bloomberg's report directly; its quotes come via The Next Web.
Sources#
- Isomorphic Labs: Isomorphic Labs announces Series C investment round (November 17, 2026)
- CNBC: Demis Hassabis' AI company raises $5 billion, months after he left as Google DeepMind CEO (November 17, 2026)
- The Next Web: Isomorphic Labs raises $5bn from Sequoia and Greenoaks for AI drug design (November 17, 2026)